Milestone Pharmaceuticals Inc Total Liabilities
Milestone Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Milestone Pharmaceuticals Inc (MIST) has total liabilities worth $67.25 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MIST asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Milestone Pharmaceuticals Inc (2017–2024)
Total liabilities of Milestone Pharmaceuticals Inc from 2017 to 2024. This chart illustrates how Milestone Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Milestone Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Milestone Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lytix Biopharma AS
OL:LYTIX
|
Norway | Nkr19.77 Million |
|
LumenRadio AB
ST:LUMEN
|
Sweden | Skr51.28 Million |
|
Abionyx Pharma SA
PA:ABNX
|
France | €7.56 Million |
|
TV Today Network Limited
NSE:TVTODAY
|
India | Rs2.38 Billion |
|
Daewon Media Co. Ltd
KQ:048910
|
Korea | ₩131.59 Billion |
|
Novotek AB
ST:NTEK-B
|
Sweden | Skr327.70 Million |
|
Ariadne Australia Ltd
AU:ARA
|
Australia | AU$18.79 Million |
|
DY Corporation
KO:013570
|
Korea | ₩448.43 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Milestone Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Milestone Pharmaceuticals Inc's balance sheet.
Liquidity & Leverage Metrics
Milestone Pharmaceuticals Inc Total Liabilities Ratios Explained
Milestone Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Milestone Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Milestone Pharmaceuticals Inc (2017–2024)
The table below shows the annual total liabilities of Milestone Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $62.35 Million | +6.67% |
| 2023-12-31 | $58.45 Million | +618.56% |
| 2022-12-31 | $8.13 Million | +12.22% |
| 2021-12-31 | $7.25 Million | +5.75% |
| 2020-12-31 | $6.86 Million | -19.46% |
| 2019-12-31 | $8.51 Million | -94.06% |
| 2018-12-31 | $143.29 Million | +136.03% |
| 2017-12-31 | $60.71 Million | -- |
About Milestone Pharmaceuticals Inc
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical tria… Read more